Prolonged urticaria and fever in a toddler

Lori Broderick, M.D., Ph.D.,1 Adriana H. Tremoulet, M.D.,2 Jane C. Burns, M.D.,2 and Hal M. Hoffman, M.D.1,2,3

ABSTRACT
We describe a 14-month-old girl who initially presented with 8 days of fever, conjunctival injection, rash, and irritability, admitted with a presumptive diagnosis of Kawasaki disease. Further history revealed intermittent urticarial-like rash since 3 months of age and pathological evaluation showed a perivascular infiltrate of neutrophils and lymphocytes. Here, we discuss the key points surrounding her diagnostic workup and our therapeutic approach.

(Case presentation)

Chief Complaint
Persistent urticaria and fever in a previously healthy child.

History of Present Illness
Our patient is a 14-month old girl, product of a full-term, fraternal twin gestation, who was initially hospitalized for 8 days with fever and rash with a presumptive diagnosis of Kawasaki disease. Evaluation revealed significantly elevated levels of acute-phase reactants and serum inflammatory markers without evidence of underlying infection. She received i.v. immunoglobulin (IVIG; 2 g/kg) initially, followed by a second dose of IVIG and subsequently infliximab (5 mg/kg), with only temporary resolution of fever, conjunctival injection, and rash. The allergy and immunology service was consulted for evaluation of persistent urticaria and fever.

Medical History
Review of our patient’s history revealed that she had experienced an intermittent rash since 3 months of age, which was initially treated as dermatographism. Two months before her presentation, her parents noted recurrence of the rash with associated conjunctivitis. The rash was associated with fever and was unique in that it appeared to worsen during the day and have near complete resolution overnight. It was described as nonpruritic and nondistressing to the patient and was accentuated in exposed areas of skin with some sparing of areas covered by clothing (Fig. 1, A and B). Antibiotics and antihistamines had no impact on either the fever or the dermatologic symptoms.

There was no history of significant infections or prolonged illness. She met her developmental milestones appropriately but was generally noted to be smaller in size than her fraternal twin. She tolerated routine vaccinations without incident.

Family History
There is no family history of urticaria, immunodeficiency, autoimmune disease, or recurrent fevers. Her parents, as well as her fraternal twin, are healthy.

Physical Examination
She initially presented as an irritable child, with weight at the 43rd percentile for age and height at 70th percentile for age. At our initial evaluation, her temperature was 40.1°C (104.1°F), and she was tachycardic. Physical exam was notable for cervical and inguinal lymphadenopathy, mild hepatosplenomegaly and multiple erythematous, blanchable macules, and patches of an urticarial nature, mostly coalescing on the upper and lower extremities, face, and torso, with minimal involvement of the palms and soles (Fig. 1, A

From the 1Departments of Medicine and 2Pediatrics, University of California–San Diego, and Rady Children’s Hospital, San Diego, California, and 3San Diego Branch, Ludwig Institute of Cancer Research, La Jolla, California
Presented initially as an abstract at the meeting of the American College of Allergy, Asthma, and Immunology (ACAAI), Boston, MA, November 5, 2011
L Broderick is funded by NIH Training Grant T32 AI 07469 during her fellowship training and has received grant support from the Thrasher Research Foundation and The Hartwell Foundation. This work is supported in part by grants from The Hartwell Foundation and The Harold Amos Medical Faculty Development Program from the Robert Wood Johnson Foundation awarded to AH Tremoulet. HM Hoffman is a consultant for Sobi Biovitrum, Novartis and Regeneron. The remaining author has no conflicts of interest to declare pertaining to this article
Address correspondence and reprint requests to Lori Broderick, M.D., Ph.D., 9500 Gilman Drive MC 0635, La Jolla, CA 92039
E-mail address: broderick@ucsd.edu
Copyright © 2012, OceanSide Publications, Inc., U.S.A.
and B). There was no evidence of skin excoriation, oral findings, or skin peeling of the fingers.

**Laboratory and Other Diagnostic Findings**

Laboratory evaluation revealed elevated levels of acute-phase reactants and serum inflammatory markers, including C-reactive protein at 22 mg/L (reference range, 0–3 mg/L), erythrocyte sedimentation rate of 43 mm/hour (reference range, 0–20 mm/hour), and platelets of 697,000/μL (reference range, 140–440 × 10^3/μL). Cultures and diagnostic tests were negative for an infectious etiology (Table 1). Multiple echocardiograms documented normal coronary artery internal dimensions.

**QUESTIONS**

**What Is the Differential Diagnosis?**

The differential diagnosis for fever and urticaria in a child is extensive, and includes infectious causes, medication reactions (especially antibiotics), autoimmune diseases, vasculitides, and autoinflammatory disorders including the cytoplasm-associated periodic syndromes (CAPS). The length of fever (>5 days), history of conjunctivitis, and presence of cervical lymphadenopathy is also concerning for Kawasaki disease, as initially diagnosed in this patient, although she did not meet the other criteria. For a diagnosis of classic Kawasaki disease, she would require at least two additional symptoms such as oral mucosal changes, polymorphous rather than urticarial rash, erythema/edema of palms/soles, or desquamation of fingertips/toes. Table 2 summarizes a more complete list of differential diagnoses.

**What Additional Laboratory Data or Investigations Would Be Helpful in Arriving at a Diagnosis in this Patient?**

Complex urticaria, as suggested by lack of responsiveness to antihistamines, association with fever, or other indications of a systemic process, should be biopsied.
Evaluation of the inflammatory infiltrate may identify rare but serious syndromes marked by urticaria, including the vasculitides and CAPS. Immunohistochemical identification of specific cell types, such as regulatory T cells (observed in cases of chronic urticaria), can guide diagnosis and management decisions. Additional histological studies such as immunofluorescent antibody staining of the tissue may provide further information regarding antibody deposition as seen in subacute cutaneous lupus.

**Clinical Course**

Treatment with IVIG at 2 g/kg led to only a temporary improvement in the fevers and inflammatory markers, but minimal impact on her rash. Subsequent treatment with infliximab at 5 mg/kg as well as a second course of IVIG (2 g/kg), gave similar results.

Given the failure of sustained improvement in her inflammatory symptoms and persistence of the urticarial rash, a skin biopsy of affected skin was performed, which showed a perivascular inflammatory infiltrate comprised of lymphocytes, neutrophils, and rare eosinophils without evidence of leukocytoclastic vasculitis. Some of the mixed inflammatory infiltrate also surrounded a few adnexal structures, suggestive of CAPS (Fig. 1, C and D).

A therapeutic trial with subcutaneous anakinra (2 mg/kg per day) resulted in partial resolution of symptoms, and increasing the dose to 4 mg/kg per day led to complete resolution of her physical symptoms as well as normalization of inflammatory markers (Fig. 2). There was no evidence of papilledema, such as blurred optic margins or hemorrhage near the optic disk on ophthalmologic exam, and laboratory studies have consistently indicated normal renal function. Additional workup revealed normal bone studies, but minimal leptomeningeal enhancement on MRI as observed in neonatal-onset multisystem inflammatory disorder. Her dose requirement and clinical findings characterize her as a more severe phenotype on the spectrum of CAPS. Sequencing of all NLRP3 coding exons failed to show a mutation.

She continues to be asymptomatic on anakinra at 4 mg/kg per day, with serum inflammatory markers at the lower limits of detection: C-reactive protein at 0.02 mg/L (reference range, 0–3 mg/L) and erythrocyte sedimentation rate at 1 mm/hour (reference range, 0–20 mm/hour). Attempts at reducing her dose to every other day administration have resulted in return of clinical symptoms. She has met developmental milestones appropriately, and her growth has improved with height and weight now surpassing those of her fraternal twin sister. Therapy with anakinra has been well tolerated and she has not experienced any injection site reactions or serious infections.

**DISCUSSION**

The pattern of symptoms and clinical findings, as well as response to anakinra, was consistent with a diagnosis of CAPS. CAPS are a spectrum of autosomal dominant disorders, characterized by intermittent or continuous symptoms of fever, rash, conjunctivitis, and musculoskeletal pain. Muckle-Wells syndrome is similarly characterized by inflammatory episodes, which occur more frequently but without a defined inciting factor. Chronic inflammation in Muckle-Wells syndrome leads to the development of progressive sensorineural hearing loss and systemic amyloidosis in a subset of patients. Muckle-Wells syndrome is similarly characterized by inflammatory episodes, which occur more frequently but without a defined inciting factor. Chronic inflammation in Muckle-Wells syndrome leads to the development of progressive sensorineural hearing loss and systemic amyloidosis in a subset of patients. Although classified as dis-

---

**Table 2 Differential diagnosis of fever and urticaria**

| Immunologic/Autoimmune | Infectious | Autoinflammatory | Other Considerations |
|-------------------------|------------|------------------|---------------------|
| Urticarial vasculitis   | Macrophage activation syndrome | Respiratory virus | CAPS                |
| SCLE/SLE                | HLH        | HIV              | Kawasaki disease    |
| Systemic onset juvenile idiopathic arthritis | Schnitzler syndrome | Parasitic infection | Malignancy |

CAPS = cryopyrin-associated periodic syndromes; HIV = human immunodeficiency virus; HLH = hemophagocytic lymphohistiocytosis; SCLE = subacute cutaneous lupus; SLE = systemic lupus erythematosus; URI = upper respiratory infection.
Distinct disorders, many patients display overlapping symptoms, as we observed in our patient. The majority of CAPS patients present within the first few weeks to months of life, consistent with the inherited nature of this systemic innate immune inflammatory disorder. However, there are several cases in which significant symptoms are not observed until after the neonatal period as was seen in our patient. This is also true for several of the other hereditary fever disorders, suggesting a role for an environmental trigger, such as microbial exposure. These autoinflammatory disorders are characterized by dysregulation of innate immunity or aberrant pattern recognition sensing, with a predominance of activated neutrophils and monocytes, rather than the antigen-specific T cells and high-titer autoantibodies observed in autoimmune diseases.

Most but not all CAPS patients have a mutation in NLRP3 which encodes cryopyrin.13 The identification of mutation-negative patients with a classic CAPS phenotype suggests the involvement of additional genes in the same or related pathways. Additionally, considerable evidence now exists for the presence of somatic mosaicism in NLRP3 in many CAPS patients initially thought to be mutant negative,14,15 but this still has not been evaluated in our patient. Cryopyrin associates with apoptosis-associated speck-like protein containing a caspase recruitment domain and pro-caspase-1 to form the NLRP3 inflammasome driving IL-1β and IL-18 production. Persistent activation of the inflammasome in CAPS leads to up-regulation of IL-1β and the symptoms observed in CAPS (Fig. 3).16

Therapies for CAPS primarily target IL-1 and include anakinra (recombinant IL-1 receptor antagonist),17,18 rilonacept (fusion protein of IL-1 receptor and IL-1 receptor accessory protein),19,20 and canakinumab (humanized monoclonal antibody to IL-1β).21 Studies with IL-1 blockers have consistently shown reduction of symptomatic periods and inflammatory markers in patients with CAPS, similar to the results observed in our patient. Additionally, anti-IL-1 therapy has often shown substantial improvement of progressive and long-term complications of CAPS, including hearing loss and renal disease due to amyloidosis, as well as improvement in quality-of-life measurements.22–24 The success of IL-1-targeted therapy in CAPS and other neutrophilic skin disorders such as Sweet syndrome25 and Schnitzler syndrome26

**Figure 2.** Select laboratory markers and response to therapy. (A) Total white blood cell count. (B) Absolute neutrophil count. (C) C-reactive protein (CRP). IVIG, i.v. immunoglobulin.

**Figure 3.** NLRP3 Inflammasome. Cyropyrin-associated periodic syndrome (CAPS)-associated mutations in NLRP3 lead to inflammasome hyperactivity, independent of known clinically relevant sterile inflammatory stimuli. Inflammasome activation results in pro-caspase-1 cleavage, caspase-1 activation, and IL-1β production leading to inflammation.
suggest that it may have a role in the therapy of chronic urticaria with neutrophilic pathology.

Currently, rilonacept and canakinumab are Food and Drug Administration approved for CAPS, whereas anakinra is only approved for the treatment of rheumatoid arthritis. All three drugs are injectable and have established life-changing results for these patients but primarily differ in their recommended frequency of administration. IL-1–targeted therapy may be associated with increased risk of nonopportunistic infection, and patients should be monitored appropriately and treated accordingly.

Final Diagnosis
Final diagnosis was cryopyrin-associated periodic syndrome.

SUMMARY AND CONCLUSIONS
This patient with mutation-negative CAPS emphasizes the broad differential diagnosis of fever and rash in a young child and the variable clinical presentation of the CAPS spectrum. This case also illustrates the usefulness of biopsy for urticarial-like lesions that are minimally responsive to conventional therapy. It also suggests that there is a role for a therapeutic trial of anakinra in the diagnostic workup of CAPS as well as long-term maintenance therapy.

ACKNOWLEDGMENTS
This study was approved by the University of California–San Diego Institutional Review Board. The authors acknowledge the clinical advice of Raphaela Goldbach-Mansky, M.D., (NIH), Shireen Ily, and clinical advice of Simon A. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. J Allergy Clin Immunol 124:1141–1149, 2009.

REFERENCES
1. McKinnon HD Jr, and Howard T. Evaluating the febrile patient with a rash. Am Fam Physician 62:804–816, 2000.
2. Monier A, Colato C, Zanoni G, et al. Urticarial lesions: If not urticaria, what else? The differential diagnosis of urticaria: Part II. Systemic diseases. J Am Acad Dermatol 62:597–570, 2010.
3. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110:2747–2771, 2004.
4. Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 109:694–700, 2002.
5. David-Bajer KM, and Davis BM. Pathology, immunopathology, and immunohistochemistry in cutaneous lupus erythematosus. Lupus 6:145–157, 1997.
6. Kolivras A, Theunis A, Ferster A, et al. Cryopyrin-associated periodic syndrome: An autoinflammatory disease manifested as neutrophilic urticarial dermatosis with additional perieccrine involvement. J Cutan Pathol 38:202–208, 2011.
7. Kieffer C, Cribier B, and Lipsker D. Neutrophilic urticarial dermatosis: A variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 88:23–31, 2009.
8. Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep 13:123–131, 2011.
9. Goldbach-Mansky R, and Kastner DL. Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol 124:1141–1149, 2009.
10. Hoffman HM, and Simon A. Recurrent febrile syndromes: What a rheumatologist needs to know. Nat Rev Rheumatol 5:249–256, 2009.
11. Hoffman HM, Wanderer AA, and Broide DH. Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108:615–620, 2001.
12. Muckle TJ, and Wellsm. Urticaria, deafness, and amyloidosis: A new heredo-familial syndrome. J Med 31: 235–248, 1962.
13. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29:301–305, 2001.
14. Saito M, Nishikomori R, Kambe N, et al. Disease-associated C1AS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood 111:2132–2141, 2008.
15. Tanaka N, Izawa K, Saito MK, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: Results of an international multicenter collaborative study. Arthritis Rheum 65:3625–3632, 2011.
16. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20:319–325, 2004.
17. Hawkins PN, Lachmann HJ, and McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 348:2583–2584, 2003.
18. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779–1785, 2004.
19. Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58:2432–2442, 2008.
20. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum 58:2432–2442, 2008.
21. Hoffman HM, Wanderer AA, and Broide DH. Familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779–1785, 2004.